120 related articles for article (PubMed ID: 24388104)
21. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
Hiscox S; Jordan NJ; Smith C; James M; Morgan L; Taylor KM; Green TP; Nicholson RI
Breast Cancer Res Treat; 2009 May; 115(1):57-67. PubMed ID: 18493848
[TBL] [Abstract][Full Text] [Related]
22. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
Xu H; Washington S; Verderame MF; Manni A
Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
24. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
25. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Hiscox S; Barrett-Lee P; Borley AC; Nicholson RI
Eur J Cancer; 2010 Aug; 46(12):2187-95. PubMed ID: 20471823
[TBL] [Abstract][Full Text] [Related]
26. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
27. Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways.
Chen PH; Peng CY; Pai HC; Teng CM; Chen CC; Yang CR
J Nutr Biochem; 2011 Aug; 22(8):732-40. PubMed ID: 21062671
[TBL] [Abstract][Full Text] [Related]
28. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.
Zhang Q; Thomas SM; Xi S; Smithgall TE; Siegfried JM; Kamens J; Gooding WE; Grandis JR
Cancer Res; 2004 Sep; 64(17):6166-73. PubMed ID: 15342401
[TBL] [Abstract][Full Text] [Related]
29. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy.
Rucci N; Recchia I; Angelucci A; Alamanou M; Del Fattore A; Fortunati D; Susa M; Fabbro D; Bologna M; Teti A
J Pharmacol Exp Ther; 2006 Jul; 318(1):161-72. PubMed ID: 16627750
[TBL] [Abstract][Full Text] [Related]
31. Activation of Src protein tyrosine kinase plays an essential role in urocortin-mediated cardioprotection.
Yuan Z; McCauley R; Chen-Scarabelli C; Abounit K; Stephanou A; Barry SP; Knight R; Saravolatz SF; Saravolatz LD; Ulgen BO; Scarabelli GM; Faggian G; Mazzucco A; Saravolatz L; Scarabelli TM
Mol Cell Endocrinol; 2010 Aug; 325(1-2):1-7. PubMed ID: 20416357
[TBL] [Abstract][Full Text] [Related]
32. SRC as a therapeutic target in breast cancer.
Morgan L; Nicholson RI; Hiscox S
Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):273-8. PubMed ID: 19075780
[TBL] [Abstract][Full Text] [Related]
33. The molecular rationale of Src inhibition in colorectal carcinomas.
Gargalionis AN; Karamouzis MV; Papavassiliou AG
Int J Cancer; 2014 May; 134(9):2019-29. PubMed ID: 23733480
[TBL] [Abstract][Full Text] [Related]
34. Pharmacology of Src family kinases and therapeutic implications of their modulators.
Kumar A; Jaggi AS; Singh N
Fundam Clin Pharmacol; 2015 Apr; 29(2):115-30. PubMed ID: 25545125
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of Src expression and activity in human neoplasia.
Chatzizacharias NA; Kouraklis GP; Giaginis CT; Theocharis SE
Histol Histopathol; 2012 Jun; 27(6):677-92. PubMed ID: 22473690
[TBL] [Abstract][Full Text] [Related]
36. Src inhibitors in breast cancer therapy.
Hiscox S; Nicholson RI
Expert Opin Ther Targets; 2008 Jun; 12(6):757-67. PubMed ID: 18479222
[TBL] [Abstract][Full Text] [Related]
37. Src kinase and pancreatic cancer.
Hilbig A
Recent Results Cancer Res; 2008; 177():179-85. PubMed ID: 18084959
[TBL] [Abstract][Full Text] [Related]
38. Redox circuitries driving Src regulation.
Giannoni E; Chiarugi P
Antioxid Redox Signal; 2014 May; 20(13):2011-25. PubMed ID: 23901911
[TBL] [Abstract][Full Text] [Related]
39. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen T; George JA; Taylor CC
Anticancer Drugs; 2006 Feb; 17(2):123-31. PubMed ID: 16428929
[TBL] [Abstract][Full Text] [Related]
40. Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells.
Djeungoue-Petga MA; Lurette O; Jean S; Hamel-Côté G; Martín-Jiménez R; Bou M; Cannich A; Roy P; Hebert-Chatelain E
Cell Death Dis; 2019 Dec; 10(12):940. PubMed ID: 31819039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
